Product Description
Volasertib is a dihydropteridinone Polo-like kinase 1 (Plk1) inhibitor with potential antineoplastic activity. Volasertib selectively inhibits Plk1, inducing selective G2/M arrest followed by apoptosis in a variety of tumor cells while causing reversible cell arrest at the G1 and G2 stage without apoptosis in normal cells. Plk1, named after the polo gene of Drosophila melanogaster, is a serine/threonine protein kinase involved in regulating mitotic spindle function in a non-ATP competitive manner. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Volasertib)
Mechanisms of Action: PLK1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: Orphan Drug - Myosarcoma|Rhabdomyosarcoma|Sarcoma *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Boehringer Ingelheim
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Acute Myeloid Leukemia|Leukemia|Stem Cell Transplant
Phase 2: Bladder Cancer|Transitional Cell Carcinoma|Kidney Diseases|Myelodysplastic Syndrome|Ovarian Cancer|Acute Myeloid Leukemia|Non-Small-Cell Lung Cancer|Leukemia|Preleukemia
Phase 1: Myelodysplastic Syndrome|T-Cell Peripheral Lymphoma|Oncology Solid Tumor Unspecified|Preleukemia|T-Cell Lymphoma|Leukemia|Acute Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Myelomonocytic Leukemia|Acute Monocytic Leukemia|Juvenile Myelomonocytic Leukemia,|Acute Erythroblastic Leukemia|Acute Megakaryoblastic Leukemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
POLO-AML-2 | P3 |
Completed |
Leukemia |
2021-05-28 |
|
2008-003617-27 | P2 |
Completed |
Leukemia |
2021-04-23 |
|
JapicCTI-132264 | P3 |
Completed |
Acute Myeloid Leukemia |
2019-10-31 |
|
NU 16H06 | P1 |
Withdrawn |
Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma |
2018-07-01 |